DUR928



NAME OF DRUG : DUR928

ALSO KNOWN AS : DUR_928

LABORATORY : DURECT

STATUS AND ADVANCEMENT

Type of drug : epigenetically-active endogenous small molecule

Clinical trials advancement : Analysing Results Phase 1

Estimated time to market : 124 months.

LABORATORY ABSTRACT ON THE DRUG

DUR-928 is the lead product candidate in DURECT’s Epigenetic Regulator Program. It is an endogenous, orally bioavailable small molecule that has been shown in nonclinical studies to modulate the activity of nuclear receptors playing an important regulatory role in lipid homeostasis, inflammation, and cell survival.

Pharmacokinetics (PK) studies in mice, hamsters, and monkeys and PK/toxicity studies in rats and dogs have shown DUR-928 to be orally bioavailable and nontoxic at plasma concentrations up to several thousand times naturally-occurring levels. Based on data from 10 nonclinical disease models involving 3 animal species, DURECT is examining the potential application of DUR-928 to human chronic metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), several nonmetabolic liver disorders, acute organ injury, and inflammatory conditions such as psoriasis.

RECENT NEWS ON DUR928

SOME PUBLICATIONS RELATED WITH DUR928

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH DUR928


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE